Boehringer Ingelheim Pharmaceuticals, Inc. has announced that it will participate in the 2015 American Thoracic Society (ATS) International Conference taking place between May 15 and 20 in Denver, and will present 29 abstracts on treatments for respiratory conditions from their portfolio. The data will address investigational treatments for chronic obstructive pulmonary disease (COPD) and asthma, as well as approved therapies for idiopathic pulmonary fibrosis (IPF) and COPD.
Nineteen of the abstracts will be focused on treating COPD, which includes novel data from the company’s phase III TONADO trials that are designed to evaluate the late-stage investigational therapy tiotropium/olodaterol Respimat. The company announced in a press release that in addition to the abstracts, which will be available on their website, there are also going to be numerous educational opportunities at the conference as well.
“We are proud of our long-standing commitment to ongoing innovation in discovering and developing new treatments for serious lung conditions where there is an unmet need,” stated the vice president for Clinical Development and Medical Affairs, Respiratory at Boehringer Ingelheim Pharmaceuticals, Danny McBryan, MD. “We look forward to sharing our asthma, IPF and late-stage COPD data at ATS, as we continue to advance our portfolio of respiratory products.”
Among the opportunities to increase knowledge on Boehringer’s products, the healthcare professionals present at the conference will be able to participate in an Industry Theater Presentation entitled “The Role of Bronchodilators in the Long-Term Maintenance Treatment of Patients With COPD: A Review of the Data,” taking place on May 18th, and a dinner symposium featuring a panel of experts called “Selection of Long-Term Maintenance Therapy for Patients With COPD.”
TONADO are trials designed to assess the safety and efficacy of tiotropium/olodaterol Respimat in participants who suffer from COPD. The investigational maintenance therapy has not yet been approved and the company is evaluating it in the ANHELTO studies as well, which aims to compare SPIRIVA HandiHaler and tiotropium/olodaterol Respimat with the use of the SPIRIVA HandiHaler alone. In addition, the WISDOM trial is meant to assess the stepwise withdrawal of inhaled corticosteroids (ICS) in COPD.
Regarding asthma, the company will present data on its phase III UniTinA-asthma program, which was designed to investigate the impact of tiotropium RESPIMAT on adults patients suffering from severe, moderate and mild symptomatic asthma. Boehringer believes that tiotropium RESPIMAT, which has also not yet been approved, may become an effective once-daily add-on therapy to manage symptoms such as wheezing, shortness of breath, chest tightness and cough.
In addition, Boehringer Ingelheim will also present data from its latest clinical studies focused on the use of OFEV capsules in patients with IPF. The presentations will feature data on phase III trials, including the phase III INPULSIS trials [extensions] that verified the safety profile of the treatment beyond 52 weeks and the phase II TOMORROW trial [extension] that evaluated safety and efficacy at 76 weeks.